NCT04370223

Ozone Auto-hemotherapy for COVID-19 Pneumonia

A Trial of Ozone Auto-hemotherapy in Adults Hospitalized With Covid-19 Pneumonia

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 208 (estimated)
• Sponsor: Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, controlled, open-label clinical trial testing the use of ozone auto-hemotherapy in hospitalized patients with Covid-19 pneumonia. Eligible patients will be randomly assigned to receive either ozone auto-hemotherapy plus standard treatment, or standard treatment alone. Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days. Standard treatment will be the one used in each hospital participating in the trial. All analyses will be done according to the intention-to-treat principle

Conditions

• COVID-19 Pneumonia

Interventions

Type	Name	Description
BIOLOGICAL	Ozone auto-hemotherapy	ozone auto-hemotherapy

Timeline

• Start date: 2020-05-25
• Primary completion: 2020-10-25
• Completion: 2020-12-25
• First posted: 2020-04-30
• Last updated: 2020-06-09

Locations

10 sites across 1 country: Spain